Per the notice below, the United States Food and Drug Administration (FDA) has announced participation in three new collaborative communities.

FDA Participates in Three New Collaborative Communities

Recently, the U.S. Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) began participating in three new collaborative communities in the medical device ecosystem: Implantable Brain-Computer Interface Collaborative Community (iBCI-CC): Aims to facilitate advances and innovation in iBCIs, to empower each user of an iBCI to lead a fuller and more independent life. OpenOximetry Collaborative Community: Seeks to improve the safety and accuracy of pulse oximeters in all populations. Smart and Autonomous Medical Systems (SaAMS) Collaborative Community: Seeks to advance the maturity, adoption, and clinical use of SaAMS to improve patient care.

Collaborative Communities

A collaborative community is a continuing forum in which private- and public-sector members, which can include the FDA, work together on medical device challenges to achieve common objectives and outcomes.  They are convened by interested stakeholders and may exist indefinitely, produce deliverables as needed, and tackle challenges with broad impacts.  Participation in collaborative communities was one of CDRH’s strategic priorities for 2018-2020 and the FDA currently participates as a member of 17 collaborative communities.  The FDA is open to participating in others.  If you have a collaborative community in which you would like the FDA to participate, e-mail: CDRHCollabCommunities@fda.hhs.gov.

Questions?